Pegaptanib of value for age-related macular degeneration

Author：

ISSN： 1173-5503

Source： PharmacoEconomics and Outcomes News, Vol.1, Iss.542, 2007-01, pp. : 1-1

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Pegaptanib: In Exudative Age-Related Macular Degeneration

By Siddiqui M. Asif A. Keating Gillian M.

Drugs, Vol. 65, Iss. 11, 2005-01 ,pp. : 1571-1577

Adis International

Access to resources Recommend Favorite

Cost Effectiveness of Pegaptanib for the Treatment of Age-Related Macular Degeneration in the UK

By Wolowacz Sorrel E.

PharmacoEconomics, Vol. 25, Iss. 10, 2007-01 ,pp. : 863-879

Adis International

Access to resources Recommend Favorite

Pegaptanib sodium for the treatment of neovascular age-related macular degeneration

By Moshfeghi Andrew A Puliafito Carmen A

Expert Opinion on Investigational Drugs, Vol. 14, Iss. 5, 2005-05 ,pp. : 671-682

Informa Healthcare

Access to resources Recommend Favorite

Pegaptanib in exudative age-related macular degeneration: profile report

By Adis International Limited

Drugs & Therapy Perspectives, Vol. 21, Iss. 12, 2005-12 ,pp. : 6-8

Adis International

Access to resources Recommend Favorite

Pegaptanib in Exudative Age-Related Macular Degeneration: A Viewpoint by Steven Schwartz

By Schwartz Steven

Drugs, Vol. 65, Iss. 11, 2005-01 ,pp. : 1578-1579

Adis International

Access to resources Recommend Favorite